Here is another site to take a look at that has a lot of infomation on both HCQ as well as other alternatives:https://c19study.com/
And then there is this. https://www.practicalpainmanagement.com/resources/news-and-research/hydroxychloroquine-covid-preventive-still-news
UK researchers looked at data from those with rheumatoid arthritis and lupus who were taking the drug prior to the pandemic in search of more clues to its efficacy.
The team analyzed data from 194,637 patients with diagnoses of either RA or SLE. Of these, 30,569 had received two or more prescriptions of HCQ in the six months prior to March 1, 2020. The patients who received HCQ were younger (median age 63 years) than non-users (median age 66 years) and primarily women (76.3%).
The researchers adjusted for variables such as sex, age, ethnicity, and use of other immunosuppressive drugs. Other variables included BMI, hypertension, diabetes, heart, liver, and respiratory disease (excluding asthma), kidney disease, and cancer. The primary outcome measure was mortality due to COVID-19, as recorded on the death certificate.
Findings: HCQ and COVID Prevention in Patients with Rheumatic Disease
Between March 1, 2020 and July 13, 2020, 547 people in the cohort with RA or SLE died of COVID-19, 70 of whom were regular users of HCQ. The difference between deaths of users and non-users was 0.008%. The results showed no evidence that previous treatment with HCQ had a beneficial effect on COVID-19 mortality.
“Taken together, our findings do not provide any strong support for a major protective effect from ongoing routine hydroxychloroquine use,” the authors wrote in their paper.4 They also pointed out that their research demonstrates the safe and effective use of the OpenSAFELY platform for studying the effects of medicines in order to inform regulatory bodies engaged in decision-making in circumstances where there is a lack high-quality randomized trial data. However, they also noted that, because of the observational nature of their study, there is a still uncertainty that can only be addressed in large scale RCTs.